Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 207

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine

Open access
De Berardis, Domenico, Rapini, Gabriella, Olivieri, Luigi, Di Nicola, Domenico, Tomasetti, Carmine, Valchera, Alessandro, Fornaro, Michele, Di Fabio, Fabio, Perna, Giampaolo, Di Nicola, Marco, Serafini, Gianluca, Carano, Alessandro, Pompili, Maurizio, Vellante, Federica, Orsolini, Laura, Martinotti, Giovanni, Di Giannantonio, Massimo · 2018 · Therapeutic Advances in Drug Safety

Abstract

Clozapine, a dibenzodiazepine developed in 1961, is a multireceptorial atypical antipsychotic approved for the treatment of resistant schizophrenia. Since its introduction, it has remained the drug of choice in treatment-resistant schizophrenia, despite a wide range of adverse effects, as it is a very effective drug in everyday clinical practice. However, clozapine is not considered as a top-of-the-line treatment because it may often be difficult for some patients to tolerate as some adverse effects can be particularly bothersome (i.e. sedation, weight gain, sialorrhea etc.) and it has some other potentially dangerous and life-threatening side effects (i.e. myocarditis, seizures, agranulocytosis or granulocytopenia, gastrointestinal hypomotility etc.). As poor treatment adherence in patients with resistant schizophrenia may increase the risk of a psychotic relapse, which may further lead to impaired social and cognitive functioning, psychiatric hospitalizations and increased treatment costs, clozapine adverse effects are a common reason for discontinuing this medication. Therefore, every effort should be made to monitor and minimize these adverse effects in order to improve their early detection and management. The aim of this paper is to briefly summarize and provide an update on major clozapine adverse effects, especially focusing on those that are severe and potentially life threatening, even if most of the latter are relatively uncommon.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/2042098618756261

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 207

Metadata

Authors
De Berardis, D., Rapini, G., Olivieri, L., Di Nicola, D., Tomasetti, C., Valchera, A., Fornaro, M., Di Fabio, F., Perna, G., Di Nicola, M., Serafini, G., Carano, A., Pompili, M., Vellante, F., Orsolini, L., Martinotti, G., & Di Giannantonio, M.
Venue
Therapeutic Advances in Drug Safety
Published
2018-02-06
Volume
9
Issue
5
Pages
237-256
ISSN
  • 2042-0986 (ISSN-L)
  • 2042-0994
OpenAlex
W2785334206
Cited by
207
References
9
FWCI
14.57
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. https://app.cochat.ai/papers/10.1177/2042098618756261
The paper
De Berardis, D., Rapini, G., Olivieri, L., Di Nicola, D., Tomasetti, C., Valchera, A., Fornaro, M., Di Fabio, F., Perna, G., Di Nicola, M., Serafini, G., Carano, A., Pompili, M., Vellante, F., Orsolini, L., Martinotti, G., & Di Giannantonio, M. (2018). Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Therapeutic Advances in Drug Safety. https://doi.org/10.1177/2042098618756261

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.